These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 7193298)

  • 1. Plasma pyridostigmine levels in myasthenia gravis.
    White MC; De Silva P; Havard CW
    Neurology; 1981 Feb; 31(2):145-50. PubMed ID: 7193298
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma pyridostigmine levels in patients with myasthenia gravis.
    Calvey TN; Chan K
    Clin Pharmacol Ther; 1977 Feb; 21(2):187-93. PubMed ID: 837637
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Steady state kinetics of pyridostigmine in myasthenia gravis.
    Sørensen PS; Flachs H; Friis ML; Hvidberg EF; Paulson OB
    Neurology; 1984 Aug; 34(8):1020-4. PubMed ID: 6540381
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Malabsorption of pyridostigmine in patients with myasthenia gravis.
    Cohan SL; Dretchen KL; Neal A
    Neurology; 1977 Mar; 27(3):299-301. PubMed ID: 557769
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The relationship of plasma levels of pyridostigmine to clinical effect in patients with myasthenia gravis.
    Davison SC; Hyman NM; Dehghan A; Chan K
    J Neurol Neurosurg Psychiatry; 1981 Dec; 44(12):1141-5. PubMed ID: 7334410
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pyridostigmine kinetics in healthy subjects and patients with myasthenia gravis.
    Breyer-Pfaff U; Maier U; Brinkmann AM; Schumm F
    Clin Pharmacol Ther; 1985 May; 37(5):495-501. PubMed ID: 3987173
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma concentration of pyridostigmine and effects in myastenia gravis.
    Chan K; Calvey TN
    Clin Pharmacol Ther; 1977 Nov; 22(5 Pt 1):596-601. PubMed ID: 199393
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantitative correlation between plasma pyridostigmine levels and neuromuscular function in myasthenia gravis.
    Milner-Brown HS; Mellenthin M; Sharma ML; Miller RG
    Neurology; 1987 May; 37(5):800-3. PubMed ID: 3574680
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Serum levels of pyridostigmine in myasthenia gravis: methods and clinical significance].
    Schumm F; Gaertner HJ; Wiatr G; Dichgans J
    Fortschr Neurol Psychiatr; 1985 Jun; 53(6):201-11. PubMed ID: 2991094
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pyridostigmine levels in myasthenia gravis.
    Kornfeld P; Mittag T; Genkins G; Papatestas AE; Horowitz SH
    Neurology; 1977 Nov; 27(11):1099. PubMed ID: 563008
    [No Abstract]   [Full Text] [Related]  

  • 11. The effect of chronic pyridostigmine administration on pyridostigmine-14C metabolism in myasthenia gravis.
    Kornfeld P; Wolf RL; Samuels AJ; Osserman KE
    Neurology; 1971 May; 21(5):550-2. PubMed ID: 5104099
    [No Abstract]   [Full Text] [Related]  

  • 12. Neuromuscular function and plasma drug levels in pyridostigmine treatment of myasthenia gravis.
    Breyer-Pfaff U; Schmezer A; Maier U; Brinkmann A; Schumm F
    J Neurol Neurosurg Psychiatry; 1990 Jun; 53(6):502-6. PubMed ID: 2166138
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The pharmacokinetics of pyridostigmine.
    Cohan SL; Pohlmann JL; Mikszewski J; O'Doherty DS
    Neurology; 1976 Jun; 26(6 PT 1):536-9. PubMed ID: 945494
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Determination of erythrocyte-bound acetylcholinesterase activity for monitoring pyridostigmine therapy in myasthenia gravis.
    Henze T; Nenner M; Michaelis HC
    J Neurol; 1991 Jul; 238(4):225-9. PubMed ID: 1895153
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of use of pyridostigmine and requirement of vecuronium in patients with myasthenia gravis.
    Tripathi M; Kaushik S; Dubey P
    J Postgrad Med; 2003; 49(4):311-4; discussion 314-5. PubMed ID: 14699228
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Renal clearance of pyridostigmine in patients with myasthenia gravis.
    Chan K; Calvey TN
    Eur Neurol; 1977; 16(1-6):69-72. PubMed ID: 615720
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Continuous infusion of pyridostigmine in the management of myasthenic crisis.
    Saltis LM; Martin BR; Traeger SM; Bonfiglio MF
    Crit Care Med; 1993 Jun; 21(6):938-40. PubMed ID: 8504663
    [No Abstract]   [Full Text] [Related]  

  • 18. Long term treatment of myasthenia gravis with azathioprine.
    Fonseca V; Havard CW
    Postgrad Med J; 1990 Feb; 66(772):102-5. PubMed ID: 2112245
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Treatment of myasthenia gravis].
    Janda A; Brandstetter A
    Dtsch Med Wochenschr; 1986 Jul; 111(27):1081-2. PubMed ID: 3720565
    [No Abstract]   [Full Text] [Related]  

  • 20. Clinical pharmacology of pyridostigmine and neostigmine in patients with myasthenia gravis.
    Aquilonius SM; Eckernäs SA; Hartvig P; Lindström B; Osterman PO; Stålberg E
    J Neurol Neurosurg Psychiatry; 1983 Oct; 46(10):929-35. PubMed ID: 6644317
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.